N-FMOC-L-Alanyl-L-2-methylproline | 186698-30-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-FMOC-L-Alanyl-L-2-methylproline
• 英文别名: (2S)-1-[(2S)-2-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)propanoyl]-2-methylpyrrolidine-2-carboxylic acid；(2S)-1-[(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoyl]-2-methylpyrrolidine-2-carboxylic acid
• CAS: 186698-30-6
• 化学式: C₂₄H₂₆N₂O₅
• 分子量: 422.481
• InChiKey: NKANBLGSTFCXAX-OWJWWREXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Fmoc-L-亮氨酸 、 Fmoc-L-异亮氨酸 、 N-FMOC-L-Alanyl-L-2-methylproline 、 2-{[(S)-1-(2-tert-Butoxycarbonylamino-acetyl)-pyrrolidine-2-carbonyl]-amino}-4-[2-carbamoyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)-ethylsulfanyl]-butyric acid 生成
  参考文献：
  名称：

  Synthesis of a cyclic-thioether peptide which binds anti-cardiolipin antibodies

  摘要：

  Thioether cyclized peptide analogue, 1, was synthesized using solid phase FMOC chemistry on HMPB-MBHA resin. alpha-Methylproline was introduced as an FMOC-alanyl-alpha-methylproline dipeptide, and the thioether was incorporated as FMOC-protected thioether tetrapeptide intermediate, 8. Compound 1 has been shown to bind anti-cardiolipin antibodies. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)01292-1
• 作为产物：
  描述：

  N-芴甲氧羰基-L-丙氨酸五氟苯酯 、 (S)-2-甲基脯氨酸 在 碳酸氢钠 、 1-羟基苯并三唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以86%的产率得到N-FMOC-L-Alanyl-L-2-methylproline
  参考文献：
  名称：

  Synthesis of a cyclic-thioether peptide which binds anti-cardiolipin antibodies

  摘要：

  Thioether cyclized peptide analogue, 1, was synthesized using solid phase FMOC chemistry on HMPB-MBHA resin. alpha-Methylproline was introduced as an FMOC-alanyl-alpha-methylproline dipeptide, and the thioether was incorporated as FMOC-protected thioether tetrapeptide intermediate, 8. Compound 1 has been shown to bind anti-cardiolipin antibodies. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)01292-1

文献信息

• APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
  申请人：——

  公开号：US20040009904A1

  公开（公告）日：2004-01-15

  aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

  本文公开了一种能够与aPL表位结合的B细胞特异性结合的aPL类似物。优化的类似物缺乏T细胞表位，可用作治疗aPL抗体介导疾病的结合物。提供了包括aPL类似物和非免疫原价位平台分子的结合物，以及新型的非免疫原价位平台分子和连接剂。公开了制备和鉴定该类似物的方法，使用该类似物进行治疗的方法和组合物，以及用于aPL抗体的诊断免疫分析的方法和组合物。
• aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
  申请人：Victoria Jess Edward

  公开号：US20050208480A1

  公开（公告）日：2005-09-22

  aPL analogs that (a) bind specifically to B cells to which an aPL epitope binds and are disclosed. Optimized analogs lack T cell epitope(s) are useful as conjugates for treating aPL antibody-mediated diseases. Conjugates comprising aPL analogs and nonimmunogenic valency platform molecules are provides as are novel nonimmunogenic valency platform molecules and linkers. Methods of preparing and identifying said analogs, methods of treatment using said analogs, methods and compositions for preparing conjugates of said analogs and diagnostic immunoassays for aPL antibodies are disclosed.

  本发明涉及aPL类似物，其(a)专门结合到aPL表位结合的B细胞上，并且已经公开披露。优化的类似物缺乏T细胞表位，可用作治疗aPL抗体介导疾病的结合物。包括aPL类似物和非免疫原性价位平台分子的结合物，以及新型非免疫原性价位平台分子和连接剂。公开了制备和鉴定所述类似物的方法，使用所述类似物的治疗方法，以及制备所述类似物的结合物和aPL抗体的诊断免疫测定方法和组合物。
• EP0833648A4
  申请人：——

  公开号：EP0833648A4

  公开（公告）日：1999-10-13
• aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
  申请人：LA JOLLA PHARMACEUTICAL

  公开号：EP0833648A1

  公开（公告）日：1998-04-08
• US6207160B1
  申请人：——

  公开号：US6207160B1

  公开（公告）日：2001-03-27